Clinical Differences between Men and Women with Psoriatic Arthritis: Relevance of the Analysis of Genes and Polymorphisms in the Major Histocompatibility Complex Region and of the Age at Onset of Psoriasis

Table 4

Distribution of most significant markers in men and women with PsA according to age at psoriasis onset (cutoff: 40 years).

(a) PsA females

Marker	Age at onset <40: 40	Age at onset >40: 15	Female controls: 55
HLA-C*06	26 (65%); OR: 9.5 (3.6–24.9), 𝑃𝑐=0.0001	5 (33%)	9 (16.4%)
HLA-C*07	20 (50%); OR: 2.9 (1.2–6.9), 𝑃𝑐=0.02	7 (46.7%)	14 (25.5%)
TNF-308A	15 (37.5%)	10 (66.7%); OR: 9.0 (2.6–31.2), 𝑃𝑐=0.0004	12 (22%)
HLA-DR17	4 (10%)	8 (53%); OR: 5.1 (1.5–17.5), 𝑃𝑐=0.01	10 (18%)
MICA-A9	25 (62.5%); OR: 3.4 (1.5–8.0), 𝑃𝑐=0.006	8 (53.3%)	18 (32.7%)
HLA-B*27	12 (30%); OR: 5.5 (1.6–18.5), 𝑃𝑐=0.005	3 (20%)	4 (7.3%)

(b) PsA males

Marker	Age at onset <40: 45	Age at onset >40: 10	Male controls: 55
HLA-C*06	26 (58%); OR: 6.2 (2.5–15.2), 𝑃𝑐=0.0001	5 (50%); OR: 4.5 (1.1–18.5), 𝑃𝑐=0.04	10 (18.2%)
MICB-CA23	1 (2.2%)	5 (50%); OR: 17.3 (3.2–94.9), 𝑃𝑐=0.001	3 (5.5%)
C1_4_4 (384)	12 (26.7%)	8 (80%); OR: 14.3 (2.7–76.6), 𝑃𝑐=0.0007	12 (22%)
MICA-A9	27 (60%); OR: 4 (1.7–9.3), 𝑃𝑐=0.001	6 (60%); OR: 4.0 (1.0–16.2), 𝑃𝑐=0.05	15 (27.3%)
HLA-B*27	19 (42.2%); OR: 9.3 (2.9–30.2), 𝑃𝑐=0.001	1 (10%)	4 (7.3%)